Exelixis price target raised to $56 from $54 at Truist
Truist raised the firm's price target on Exelixis to $56 from $54 and keeps a Hold rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for co